Rapid, comprehensive analysis of the dystrophin transcript by a custom micro-fluidic exome array

Area of Science:

• Genetics
• Molecular Biology
• Biomarker Discovery

Background:

• Duchenne and Becker muscular dystrophies stem from mutations in the large dystrophin gene.
• Accurate molecular diagnosis is challenging due to gene size and mutation diversity.
• RNA analysis is often crucial for identifying mutations and validating their functional impact on dystrophin gene exon composition.

Purpose of the Study:

• To design and validate a novel, user-friendly platform, FluiDMD, for comprehensive molecular profiling of dystrophinopathies.
• To assess the platform's capability in defining exon composition, profiling dystrophin isoforms, and detecting mRNA decay changes.
• To demonstrate FluiDMD's efficacy in identifying all types of dystrophin gene mutations and validating their pathogenic effects.

Main Methods:

• Development of the FluiDMD platform utilizing Applied Biosystems 7900HT TaqMan low-density array technology.
• Experimental validation of the platform's performance in analyzing dystrophin gene transcripts.
• Application of the platform to various cell/tissue types, including skin biopsies.

Main Results:

• FluiDMD successfully defines full-exon composition and profiles dystrophin isoforms.
• The platform accurately detects mRNA decay changes and identifies deletions, duplications, and splicing mutations.
• FluiDMD demonstrates high sensitivity and efficacy in detecting pathogenic effects of all dystrophin mutation categories.

Conclusions:

• FluiDMD is a validated diagnostic biomarker for molecular profiling of dystrophinopathies.
• The platform offers a simple, sensitive, and effective tool for diagnosing Duchenne and Becker muscular dystrophies.
• FluiDMD's ability to use minimally invasive samples like skin enhances its clinical utility.